Prognostic impact of the components of progressive disease on survival after first-line tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma

Takashi Ikeda¹,², Hiroki Ishihara¹, Toshio Takagi¹, Tsunenori Kondo³, Kazuhiko Yoshida¹, Junpei Iizuka¹, Kazunari Tanabe¹

¹Department of Urology, Kidney Center, Tokyo Women’s Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, Japan, 162-8666

²Department of Urology, Saiseikai Kawaguchi General Hospital, 5-11-5 Nishikawaguchi, Kawaguchi City, Saitama, Japan, 332-8558

³Department of Urology, Tokyo Women’s Medical University Medical Center East, 2-1-10 Nishiogu, Arakawa-ku, Tokyo, Japan, 116-8567
Electronic Supplementary Material Legends

**Electronic Supplementary Material 1.** Flowchart of patient selection

TKI, tyrosine kinase inhibitor

**Electronic Supplementary Material 2.** (A) Progression-free survival and (B) overall survival for the entire study group.

**Electronic Supplementary Material 3.** Overall survival after first-line therapy failure according to the components of progressive disease

Overall survival after first-line tyrosine kinase inhibitor therapy failure was compared between patients (A) with or without TLG and (B) with TLG alone and NLA alone.

TLG, target lesion growth; NLA, new lesion appearance
Patients receiving first-line TKI therapy between January 2007 and March 2017 (n = 188)

Exclusion:
- Treatment continuation at the end of follow-up (n = 29)
- Discontinuation because of adverse events (n = 21)

Patients who had progressive disease after first-line TKI therapy (n = 138)

Exclusion:
- Prior cytokine therapy (n = 1)
- Short treatment duration (n = 4)
- Hemodialysis or kidney transplantation (n = 17)

Patients ultimately included (n = 116)
Median 8.7 months (95% CI: 6.4 – 10.3)

Median 20.6 months (95% CI: 17.1 – 25.6)

Electronic Supplementary Material 2
(A) TLG

<table>
<thead>
<tr>
<th>With</th>
<th>8.3 months (95% CI: 5.0 – 9.9)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Without</td>
<td>16.8 months (95% CI: 5.7 – 29.5)</td>
</tr>
</tbody>
</table>

p = 0.0142

(B) TLG alone

<table>
<thead>
<tr>
<th>TLG alone</th>
<th>8.3 months (95% CI: 4.9 – 13.1)</th>
</tr>
</thead>
<tbody>
<tr>
<td>NLA alone</td>
<td>16.8 months (95% CI: 5.7 – 29.5)</td>
</tr>
</tbody>
</table>

p = 0.0773

Electronic Supplementary Material 3